Active not recruiting
A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
I5B-MC-JGDP - ClinicalTrials.gov - NCT03086369
The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer.
How long will I be in the trial?
Your participation may continue for as long as you and your study doctor feel that you are benefiting from the study treatment.
Active not recruiting
A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
I5B-MC-JGDP - ClinicalTrials.gov - NCT03086369
The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer.
How long will I be in the trial?
Your participation may continue for as long as you and your study doctor feel that you are benefiting from the study treatment.
Key Requirements
Age :
18+
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participant must have metastatic (Stage 4) pancreatic cancer diagnosis
Participant must have tumor tissue available or be willing to provide a biopsy
Participant must have discontinued all previous treatments for cancer at least 4 weeks prior
Participant must have a life expectancy of at least 3 months
Participants must NOT
Participant must not have had first line treatment for metastatic pancreatic cancer
Participant must not have participated in another clinical trial within the last 30 days - Female participant must not have a positive pregnancy test or be lactating
Trial Summary
Conditions the trial is for
Pancreatic Cancer
What the trial is testing?
Olaratumab, Nab-paclitaxel, Gemcitabine, Placebo
Could I receive a Placebo?
yes
Enrollment Goal
186
Trial Dates
June 2017 - January 2022
Trial Phase
1
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participant must have metastatic (Stage 4) pancreatic cancer diagnosis
Participant must have tumor tissue available or be willing to provide a biopsy
Participant must have discontinued all previous treatments for cancer at least 4 weeks prior
Participant must have a life expectancy of at least 3 months
Participants must NOT
Participant must not have had first line treatment for metastatic pancreatic cancer
Participant must not have participated in another clinical trial within the last 30 days - Female participant must not have a positive pregnancy test or be lactating
Trial Summary
Conditions the trial is for
Pancreatic Cancer
What the trial is testing?
Olaratumab, Nab-paclitaxel, Gemcitabine, Placebo
Could I receive a Placebo?
yes
Enrollment Goal
186
Trial Dates
June 2017 - January 2022
Trial Phase
1
Not the right fit? Sign up to receive updates on new trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Pancreatic Cancer Resources
